记者丨张嘉钰 编辑丨江佩霞 2月24日，美股三大指数小幅高开，截至23:25，道指涨近1%涨超400点，纳指涨0.9%，标普500指数涨 0.61%。 美股大型科技股盘前涨跌互现，科技七巨头涨多跌少，苹果涨近3%，谷歌、Meta跌超1%。据智通财经 消息，Meta据称计划在今年晚些时候进军稳定币领域。 芯片股多数上涨，AMD涨超7%，台积电涨逾3%，美光科技涨逾2%。消息面上，据中国基金报报道， Meta（Facebook和Instagram母公司）在承诺使用数百万颗英伟达处理器进行AI扩张的一周后，又与超威 半导体（AMD）签署了另一项巨额芯片协议。协议的具体条款尚未披露，但听取了交易简报的巴贾林 估计，该协议在至少四年内的价值将达数百亿美元。 据新华社报道，为更便捷部署专用于人工智能(AI)的数据中心卫星网络，美国太空探索技术公司首席执 行官埃隆·马斯克设想，从月球用电磁弹射方式向地球轨道发射卫星。 | 名称 | 现价 | 涨跌幅 ▼ | | --- | --- | --- | | 超威半导体(AMD) | 210.573 | 7.11% | | ARM | 130.940 | 5.78% | | ** ...

吉利德科学同意以每股115美元现金加未来还有机会额外获得的每股最高5美元的或有付款（隐含价值78 亿美元）收购Arcellx，获得其用于多发性骨髓瘤的BCMA CAR-T疗法anito-cel的完全控制权，该药物的 FDA PDUFA日期为2026年12月23日。 责任编辑：张俊 SF065 吉利德科学同意以每股115美元现金加未来还有机会额外获得的每股最高5美元的或有付款（隐含价值78 亿美元）收购Arcellx，获得其用于多发性骨髓瘤的BCMA CAR-T疗法anito-cel的完全控制权，该药物的 FDA PDUFA日期为2026年12月23日。 责任编辑：张俊 SF065 ...

Core Viewpoint - Novo Nordisk's CagriSema did not demonstrate non-inferiority in weight loss effectiveness compared to Eli Lilly's tirzepatide, resulting in a significant drop in Novo Nordisk's stock price while Eli Lilly's stock price increased [1] Group 1 - Novo Nordisk reported that CagriSema's weight loss results were not as effective as those of tirzepatide from Eli Lilly [1] - The announcement led to a substantial decline in Novo Nordisk's stock price [1] - In contrast, Eli Lilly's stock price experienced an increase following the news [1]

Core Insights - Chengdu has established two trillion-level industrial clusters, 13 hundred-billion-level industrial chains, and 14 hundred-billion-level parks, leading among vice-provincial cities in terms of national advanced manufacturing clusters and national characteristic industrial clusters for small and medium-sized enterprises [1] - The city has adopted a "one enterprise leads one chain, one chain forms a cluster" model to support the development of its "9+9+10" modern industrial system, with the total output value of 13 manufacturing industrial chains accounting for over 70% of the industrial output value, showing a year-on-year growth of 12.1% [1] - By 2025, Chengdu plans to attract 380 major projects, accelerate the construction of 303 key projects, and complete an annual investment of 110 billion yuan [1] Group 1 - Chengdu's manufacturing industrial chains have five chains with comprehensive strength ranking in the top five nationwide [1] - The city has seen breakthroughs in brand building with notable companies emerging, such as Xin Yisheng and Bai Li Tianheng, alongside popular products and parks like Nezha IP and Tianfu Changdao [1] - Chengdu has established 141 pilot platforms for technology and industry integration, implementing 135 key core technology projects [1] Group 2 - In 2026, Chengdu will focus on eight major tasks, including cultivating business entities, promoting major projects, and enhancing technology-industry integration [2] - The city aims to cultivate over 80 specialized and innovative "little giants" and more than 300 "tomorrow stars" through a structured enterprise cultivation program [2] - Chengdu plans to introduce over 550 major industrialization projects and accelerate the construction of over 450 key projects, with an annual investment target exceeding 149 billion yuan [2]

Group 1 - Trump's 10% global tariff has taken effect, leading to a slight increase in U.S. stock indices, with the Nasdaq up 0.06%, S&P 500 up 0.01%, and Dow Jones up 0.04% [1] - AMD shares rose by 7.7% following a significant AI chip and equipment procurement agreement with Meta, valued at a total of $100 billion [1] - Novo Nordisk shares fell nearly 3% and Eli Lilly dropped over 1% as Novo Nordisk announced a price reduction of up to 50% for its weight loss drugs in the U.S. next year [1] Group 2 - Financial technology company, Futu Holdings, saw a 1.8% increase in shares after forming a long-term partnership with Anthropic, aimed at providing customizable AI agents for mid-market enterprises [1] - SanDisk shares increased by 2.1% after the company released a teaser poster, indicating the launch of a new product or technology on February 24 [1]

周二，礼来(LLY.US)股价盘前走低，截至发稿，该股跌超1.5%，报1042.5美元。消息面上，礼来主要竞 争对手诺和诺德(NVO.US)宣布，将下调旗下多款GLP-1类药物在美国的官方标价。 诺和诺德表示，自2027年1月1日起，公司将下调Wegovy、Ozempic和Rybelsus在美国市场的批发采购 价。调整后，Wegovy和Ozempic的标价将较当前水平下调约35%至50%，相关调整同时适用于注射剂型 和口服剂型。 具体来看，此次定价改革将把Wegovy注射剂和口服版本，以及Ozempic注射剂和Rybelsus口服药的月度 标价统一降至675美元。目前，在利润丰厚的抗肥胖药物市场中，诺和诺德的市场表现仍落后于礼来。 公司还指出，价格下调预计将尤其利好自付费用与官方标价挂钩的患者。不过，诺和诺德强调，此次调 整不会影响其直面消费者的自费定价体系。 诺和诺德在声明中表示，此次降价适用于上述药物的所有剂量，体现了公司在美国医疗体系不断演变的 背景下，提升患者以及公共和私人支付方用药可负担性的承诺。 ...

（原标题：美股异动 | 礼来(LLY.US)盘前跌超1.5% 竞争对手诺和诺德(NVO.US)宣布下调GLP-1药物标 价） 智通财经APP获悉，周二，礼来(LLY.US)股价盘前走低，截至发稿，该股跌超1.5%，报1042.5美元。消 息面上，礼来主要竞争对手诺和诺德(NVO.US)宣布，将下调旗下多款GLP-1类药物在美国的官方标 价。 具体来看，此次定价改革将把Wegovy注射剂和口服版本，以及Ozempic注射剂和Rybelsus口服药的月度 标价统一降至675美元。目前，在利润丰厚的抗肥胖药物市场中，诺和诺德的市场表现仍落后于礼来。 诺和诺德在声明中表示，此次降价适用于上述药物的所有剂量，体现了公司在美国医疗体系不断演变的 背景下，提升患者以及公共和私人支付方用药可负担性的承诺。 公司还指出，价格下调预计将尤其利好自付费用与官方标价挂钩的患者。不过，诺和诺德强调，此次调 整不会影响其直面消费者的自费定价体系。 诺和诺德表示，自2027年1月1日起，公司将下调Wegovy、Ozempic和Rybelsus在美国市场的批发采购 价。调整后，Wegovy和Ozempic的标价将较当前水平下调约35%至50 ...

Group 1 - The core viewpoint of the articles highlights the continued high demand for Chinese innovative drugs in global markets, with significant business development (BD) transactions occurring in early 2026, indicating a strong growth trajectory for the industry [1][2]. - As of February 15, 2026, there have been 39 license-out transactions for Chinese innovative drugs, with an upfront payment of approximately $2.953 billion and a total value exceeding $49 billion, surpassing one-third of the total amount for 2025 [1]. - Morgan Stanley's report emphasizes a positive long-term outlook for the Chinese pharmaceutical industry, identifying "catalysts" as a key theme, with expectations for numerous catalysts in 2026 that will enhance the global value of domestic pharmaceutical assets [2]. Group 2 - Morgan Stanley specifically mentions that 2025 saw a total BD transaction amount of $135.7 billion for Chinese innovative drugs, surpassing the U.S. for the first time, with 2026 showing even stronger growth as the first 49 days of transactions exceeded any single quarter in 2025 [2]. - The report highlights Hengrui Medicine as a preferred investment target, predicting accelerated sales growth in 2026 and a positive trend in new cooperative transactions, which are crucial for realizing milestone payments [2]. - The transformation of Kangzhe Pharmaceutical towards innovative drugs is noted, with the approval of a targeted drug for vitiligo, indicating a significant step in the company's transition and growth strategy [3]. Group 3 - Despite the ongoing BD transaction boom, the innovative drug sector is experiencing a market downturn, with the Hong Kong innovative drug ETF dropping 0.78% after the Spring Festival, indicating a disconnect between market sentiment and fundamentals [4]. - The focus of BD transactions in 2026 is shifting towards early-stage research projects, with over 50% of the 39 transactions being in preclinical stages, reflecting a strategic pivot in the industry [5]. - Companies like Kangfang Biotech are optimistic about the global impact of Chinese innovative drugs, aiming to expand their global footprint and enhance their international presence in drug development [5].

作为中国医药工业体系中的"隐形巨擘"，某总部位于华东的医药集团（以下简称"该集团"或"集团"）长 期占据中国医药工业百强榜首位置，其发展历程是中国本土药企从"仿制药规模化"向"创新药差异化"转 型的经典缩影。 本报告对该集团进行了全方位的解构，核心发现包括： 1. 集团概况与历史沿革：从地方小厂到行业巨头 1.1 创始背景与早期积累（1971-2000） 该集团的历史可以追溯到1971年。创始人在江苏省泰州市的一个口岸镇创办了集团的前身。创业初期， 企业主要以生产板蓝根、维生素等基础药物为主，不仅面临资金短缺，更受限于当时计划经济体制下的 统购统销模式。 在1980年代至1990年代，创始人敏锐地抓住了中国医疗卫生体制改革的机遇，确立了"质量兴企"的战略 基石。不同于当时许多乡镇企业追求短期利益的做法，该集团在早期就建立了严格的质量内控标准，这 为其后来在"板蓝根大战"等行业洗牌中脱颖而出奠定了基础。集团充分利用长三角（上海、苏州、杭 州）的地理优势，逐步建立了覆盖华东、辐射全国的销售网络。 1.2 爆发式增长与行业霸主地位（2000-2019） 进入21世纪，该集团迎来了黄金发展期。2003年至2010年间 ...

诺和诺德宣布大幅下调明星减肥药Wegovy及Ozempic在美国市场的标价，司美格鲁肽系列药物月度标价统一为675美元，降幅最高达50%，新定价 将于明年1月1日生效。此举标志着这家丹麦药企在肥胖症市场的竞争策略出现重大转向。 消息公布后，诺和诺德美股盘前下跌3%，礼来美股盘前一度跌逾4%。值得注意的是，诺和诺德本周一刚公布下一代药物CagriSema又一组令人失 望的试验数据，此后股价已累计下跌约19%。降价决定在此背景下出炉，进一步加剧市场担忧。 此次降价是诺和诺德在肥胖症市场竞争中失去领先地位后的主动应对。礼来竞品Zepbound目前标价为每月1086.37美元，诺和诺德统一定价至675 美元后，在标价层面形成明显价格优势。 诺和诺德美国业务负责人Jamey Millar表示，此次降价不会对公司净销售额产生直接影响，但对获得支付方认可持乐观态度。Millar曾任职于 UnitedHealth Group旗下药品福利管理机构Optum Rx，深谙美国药品定价策略。他表示： "支付方此前已公开呼吁降低药品标价，我有信心他们将接受并欢迎这些更低的标价。" 高免赔额计划患者受益最大 此次降价针对的是批发采购成本 ...